WI Harper Group-backed Amwise Diagnostics closes Series B round, achieving accurate prognosis assessment of breast cancer in Asia
[vc_row][vc_column][vc_column_text]WI Harper Group| 2020-02-29[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]The following article comes from 动脉新医药 Author 徐文娟[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1583660945374{background-color: #e5e5e5 !important;}”]Recently, WI Harper-backed Amwise Diagnostics,successfully completed the first close of its B round financing. This financing is led by Jiangsu Simcere Pharmaceutical Co., Ltd, a subsidiary of SimcereHoldings.…